Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
25066675
DOI
10.1016/j.jsbmb.2014.07.007
PII: S0960-0760(14)00131-9
Knihovny.cz E-resources
- Keywords
- 11β-hydroxysteroid dehydrogenase, Adipose tissue, Brain, Colon, Endocrine disruptor, Inhibitor, Placenta, Testis,
- MeSH
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 antagonists & inhibitors metabolism MeSH
- 11-beta-Hydroxysteroid Dehydrogenase Type 2 antagonists & inhibitors metabolism MeSH
- Diabetes Mellitus chemically induced enzymology pathology MeSH
- Endocrine Disruptors pharmacology MeSH
- Glucocorticoids metabolism MeSH
- Enzyme Inhibitors pharmacology MeSH
- Colon drug effects enzymology MeSH
- Humans MeSH
- Metabolic Syndrome chemically induced enzymology pathology MeSH
- Brain drug effects enzymology MeSH
- Neoplasms chemically induced enzymology pathology MeSH
- Obesity chemically induced enzymology pathology MeSH
- Organ Specificity MeSH
- Placenta drug effects enzymology MeSH
- Pregnancy MeSH
- Testis drug effects enzymology MeSH
- Adipose Tissue drug effects enzymology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 MeSH
- 11-beta-Hydroxysteroid Dehydrogenase Type 2 MeSH
- Endocrine Disruptors MeSH
- Glucocorticoids MeSH
- Enzyme Inhibitors MeSH
Numerous chemicals in the environment have the ability to interact with the endocrine system. These compounds are called endocrine disruptors (EDs). Exposure to EDs represents one of the hypotheses for decreasing fertility, the increased risk of numerous cancers and obesity, metabolic syndrome and type 2 diabetes. There are various mechanisms of ED action, one of which is their interference in the action of 11β-hydroxysteroid dehydrogenase (11βHSD) that maintains a balance between active and inactive glucocorticoids on the intracellular level. This enzyme has two isoforms and is expressed in various tissues. Inhibition of 11βHSD in various tissues can have different consequences. In the case of EDs, the results of exposure are mainly adverse; on the other hand pharmaceutically developed inhibitors of 11βHSD type 1 are evaluated as an option for treating metabolic syndrome, as well as related diseases and depressive disorders. This review focuses on the effects of 11βHSD inhibitors in the testis, colon, adipose tissue, kidney, brain and placenta.
References provided by Crossref.org
